The mask is designed to reduce hypoxia in the eye which is present at some level in everyone with diabetes. Therefore, people with any stage of diabetic retinopathy can use the mask. 

Noctura 400 can be used in parallel with the standard treatments and may reduce the need for or the frequency of the other interventions. Patients are always advised to follow the advice of their eye specialist and if standard treatments such as laser or intravitreal injections are being recommended by their ophthalmologist, patients should continue to follow that advice.  

Unlike some of the other diabetic retinopathy treatments, the light from Noctura 400 will not cause cataracts or glaucoma. Patients who already have these conditions should first seek advice from their eye specialist before using Noctura 400. 

Patients with diagnosed sleep apnoea may need to use a CPAP machine to provide oxygen at night. Noctura 400 can be used at the same time as the CPAP machine as the area that the light mask covers will not usually impact the area covered by the oxygen mask. 

The mask is available in the UK from a number of independent high street optometrists as well as from the Outside Clinic, a national home-visiting optician. Please contact us for further information and we can put you in contact with a supplier near you. 

Noctura 400 has been evaluated within the NHS and we are working towards it being available directly through the NHS. Please check www.polyphotonix.com and www.noctura.com for latest news. 

Noctura 400 is also available in Portugal. Please contact us for availability elsewhere and we'll do our best to supply it to you. 

Noctura 400 is non-invasive and very safe to use. The wavelength of the green light is within the normal visible spectrum and not at all dangerous. The brightness of the light is at a comfortably low level and will not cause damage. The mask has been tested for both safety and efficacy and has been awarded the CE Mark as a Class IIa medical device. 

Noctura 400 has undergone extensive design usability trials and includes a comfortable fabric mask which has been ergonomically designed with comfort in mind. Some people may find it unusual for the first couple of weeks, but most people soon become accustomed to it and wearing it becomes a normal part of their night-time routine. 

The wavelength (colour) and the low intensity (brightness) of the light has been specifically selected to minimise sleep disturbance. Most people find that they quickly become accustomed to the light and can ignore it. 

The mask should be worn during normal hours of sleep and has been designed to shine light through closed eyelids. However, if someone looks directly at the light or sleeps with their eyes open it will not cause any problems, as it is a low intensity light and well within the visible spectrum. 

Some patients do see an improvement in their eyesight, but not everyone should expect to notice any significant improvement in visual acuity. It depends on the patient’s condition and stage of their eye disease. 

Noctura 400 has undergone extensive safety trials and there is no indication it will make your sight worse. Patients must attend their prescribed check-ups with their eye specialist and if sight is in decline there may be another underlying problem that requires attention. 

Noctura 400 has been designed to be a continuous treatment to be used every night. Taking a break from using the mask could lead to further hypoxia which is one of the main causes of retinopathy in people with diabetes. As long as diabetes is present, retinopathy has the chance to develop.  

Noctura 400 has not been tested on anyone under the age of 18 or on women who are pregnant, and therefore must not be used by these groups of patients.  

Noctura 400 is a treatment for diabetic retinopathy and diabetic macular oedema and can only be used as a treatment for these diabetes related conditions. Noctura 400 is not intended to be used for other eye conditions such as age-related macular degeneration (AMD), retinal vein occlusion (RVO) or pseudoxanthoma elasticum (PXE).